Nanobiotechnology Market By Technology 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Nanobiotechnology Market
Nanobiotechnology Market: By Technology (Nanocrystals, Nanoparticles, Liposomes, others), By Application (neurology, oncology, cardiovascular/physiology, anti-inflammatory/immunology, anti-infective, others) & By Region-Forecast (2016-2021)
Report Code : HCR 0298
Updated Date: 03 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Nanobiotechnology Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Nanobiotechnology Market– Market Forces
   4.1. Drivers
      4.1.1. Development of efficient and advance technology
      4.1.2. Technological advancements and rising interest
   4.2. Restraints
      4.2.1. Higher cost of research and development
   4.3. Opportunities
      4.3.1. Emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Nanobiotechnology Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Nanobiotechnology Market, By Technology
   6.1. Nanocrystals
   6.2. Nanoparticles
   6.3. Liposomes
   6.4. Micelles
   6.5. Nanotubes
   6.6. others
7. Nanobiotechnology Market, By Application
   7.1. Neurology
   7.2. Oncology
   7.3. Cardiovascular/physiology
   7.4. Anti-inflammatory/immunology
   7.5. Anti-infective
   7.6. Others
8. Nanobiotechnology Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Nanobiotechnology – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   10.1. AbbVie, Inc
   10.2. Amgen, Inc
   10.3. Celgene Corporation
   10.4. Johnson & Johnson
   10.5. Merck & Co., Inc
   10.6. Novartis International AG
   10.7. 3M company
   10.8. AMSC Corporation
   10.9. Agilent Technologies Inc
   10.10. Bayer AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Nanobiotechnology applications are defined comprehensively as the creation and use of materials, devices and systems through the manipulation of matter at scales of less than 100 nanometres. Globally, Development of efficient and advance technology, technological advancements and rising interest and uses in various industries are the prime growth drivers of global Nanobiotechnology market. In addition, increase in adoption of Nanobiotechnology for pharmaceutical and semiconductors, and emerging economies such as China, India and others, will create new opportunities for global Nanobiotechnology market. However, higher cost of the research and development, and complex manufacturing process are the key restraints for global Nanobiotechnology market.

 Nanobiotechnology Market

Geographically North America dominated global Nanobiotechnology market, with approximately half of the world’s procedures being done in the U.S. because of rising nanoparticles used to reinforce tires and other rubber products; photographic silver and dye nanoparticles. Europe is projected to have fastest growth, owing to the favourable growth conditions for pharmaceutical and biotechnology manufacturers due to clinical trial success and eventual Food and Drug Administration (FDA) approval. Among all the applications, neurology segment has the highest market share in global Nanobiotechnology market.

This report identifies the global Nanobiotechnology market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global Nanobiotechnology market.

This report segments global Nanobiotechnology market on the basis of type, procedures, and regional market as follows:
  • Nanobiotechnology Market, By Technology: nanocrystals, nanoparticles, liposomes, micelles, Others
  • The report has focused study on Nanobiotechnology market by basis of Application: neurology, oncology, cardiovascular/physiology, anti-inflammatory/immunology, anti-infective, Others
  • This report has been further segmented into major regions, which include detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region. The major countries considered under the Asia-Pacific region are India, China, South Korea and Japan. The major countries considered under the European region are Germany, U.K., France, Italy, Spain and Russia. The major countries considered under the North American region are United States, Canada and Mexico

This report identifies all the major companies operating in the Nanobiotechnology market. Some of the major companies’ profiles in detail are as follows:
  • AbbVie, Inc
  • Amgen, Inc
  • Celgene Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.

Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports